Please assess the completion status of the following clinical trial:

Trial Title: Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females age 25-65 with diagnosis of alcohol dependence, as ascertained using the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV version);~2. Concerned about their drinking, but not planning to pursue any other form of treatment at present (12-step meetings are not considered treatment);~3. Able to provide voluntary informed consent;~4. Having at least 2 heavy drinking days in the past 30 days;~5. Willing to commit to the goal of abstinence at least from the time of the first psilocybin administration session until the end of treatment.~6. At least 24 hours abstinence from alcohol at the time of the psilocybin administration sessions;~7. If female of childbearing potential, willing to use approved form of contraception from screening until after the psilocybin administration sessions;~8. Having a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions; and~9. Able to provide adequate locator information.~Exclusion Criteria:~1. Exclusionary medical conditions (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, uncontrolled hypertension, history of cerebrovascular accident, severe obesity (BMI greater than or equal to 35);~2. Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depression, current post-traumatic stress disorder, current suicidality);~3. A family history of schizophrenia, schizoaffective disorder, bipolar disorder, or suicide (first or second degree relatives);~4. Lifetime history of hallucinogen use on more than 10 occasions, or any use in the past 30 days;~5. Cocaine, psychostimulant, or opioid dependence (past 12 months) or current (past 30 days) use;~6. A history of medically significant suicide attempt or violent crime;~7. Significant alcohol withdrawal (CIWA-Ar score greater than 7);~8. Exclusionary laboratory abnormalities (any liver function test (LFT) greater than 5 times normal, ECG evidence of ischemia, serious abnormalities of complete blood count or chemistries);~9. Active legal problems with the potential to result in incarceration;~10. Pregnancy or lactation;~11. The need to take excluded medication (e.g., antidepressants, antipsychotics, psychostimulants, pharmacologic treatments for addictions).~12. High risk of adverse emotional reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of meaningful social support).

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- psilocybin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete